Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acrolein and related reactive electrophiles, collectively known as Reactive Carbonyl Species (RCS), are highly reactive alpha,beta-unsaturated aldehydes generated primarily through lipid peroxidation and the metabolism of certain drugs or environmental pollutants (PubChem CID 7847). These molecules possess a strong affinity for nucleophilic groups on proteins, DNA, and lipids, leading to the formation of stable covalent adducts via Michael addition or Schiff base reactions (PMID: 18457515). This chemical modification, termed carbonylation, results in protein dysfunction, DNA damage, and the activation of pro-inflammatory and pro-apoptotic pathways (PMID: 21723373). Pathologically, acrolein is a significant mediator of secondary injury in spinal cord trauma and plays a critical role in the demyelination process of Multiple Sclerosis (PMID: 24933103). Furthermore, acrolein is the primary causative agent of hemorrhagic cystitis following cyclophosphamide therapy (StatPearls: Mesna). Therapeutic intervention involves the use of scavenging agents, such as hydralazine or mesna, which contain nucleophilic moieties that compete with cellular targets to neutralize these electrophiles (PMID: 25653143). By sequestering these reactive species, scavengers mitigate oxidative damage and preserve cellular integrity across various neurodegenerative and inflammatory conditions.
Direct chemical neutralization through nucleophilic scavenging, typically via Michael addition or Schiff base formation, to prevent the electrophiles from forming damaging adducts with cellular proteins and DNA.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acrolein and related reactive electrophiles (RCS).